Amgen-AstraZeneca Drug Combo Dramatically Boosts Survival in Aggressive Lung Cancer

A groundbreaking drug combination by Amgen and AstraZeneca has delivered an unprecedented 58% reduction in the risk of death for patients with extensive-stage small cell lung cancer (ES-SCLC), a notoriously aggressive form of the disease. The pairing of Amgen Imdelltra (tarlatamab-dlle) and AstraZeneca Imfinzi (durvalumab), used as a first-line maintenance treatment, extended median overall survival by more than eight months, to 21.1 months, compared to 12.7 months for Imfinzi alone. This landmark data, presented at the European Society for Medical Oncology (ESMO) Congress 2026, marks a significant leap forward in a cancer where advancements have historically been hard-won. Small cell lung cancer, particularly at its extensive stage, has long presented a grim prognosis, with many patients relapsing quickly after initial chemotherapy and immunotherapy, and a median overall survival rarely exceeding 13 months with previous first-line treatments. The DeLLphi-305 study findings are especially impactful as they demonstrate the benefit of introducing Imdelltra, a bispecific T-cell engager, earlier in the treatment pathway. Amgen Chief Medical Officer, Paul Burton, has called these results a 'watershed moment,' suggesting a fundamental shift in how this aggressive cancer could be managed. Beyond extending life, the combination also drastically cut the risk of disease progression or death by 66%. With these compelling Phase 3 results now simultaneously published in The New England Journal of Medicine, attention will turn to regulatory bodies for potential approvals to integrate this combination into standard first-line maintenance care. Imdelltra already received accelerated FDA approval in May 2024 (and traditional approval in November 2025) for patients whose ES-SCLC progressed after initial chemotherapy, but its earlier use could vastly improve patient outcomes. While the treatment presents a higher rate of some adverse events like Cytokine Release Syndrome (CRS), ongoing monitoring and management strategies are in place, offering new hope for a patient population in dire need of more effective therapies.